Nanovibronix (NASDAQ:NAOV) Announces Quarterly Earnings Results

Nanovibronix (NASDAQ:NAOV) released its quarterly earnings data on Friday. The company reported ($0.91) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.72 million during the quarter. Nanovibronix had a negative return on equity of 45.24% and a negative net margin of 380.29%.

Nanovibronix Price Performance

Nanovibronix stock traded down $0.27 during midday trading on Friday, hitting $4.42. 6,978 shares of the stock were exchanged, compared to its average volume of 511,755. Nanovibronix has a 1 year low of $4.40 and a 1 year high of $162.50. The firm has a market cap of $4.47 million, a P/E ratio of -0.05 and a beta of 2.16. The company has a 50 day moving average price of $6.00 and a two-hundred day moving average price of $10.31.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Nanovibronix in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Nanovibronix Company Profile

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.